Manila COVID-19 Field Hospital gagawing quarantine facility sa mga OFW na positibo sa virus

By Chona Yu December 31, 2021 - 11:30 AM

Gagamitin na ngayon ang Manila COVID-19 Field Hospital sa Luneta bilang bagong quarantine facility para sa mga umuuwing overseas Filipino workers na magpo-positibo sa virus.

Ayon kay Manila Mayor Isko Moreno, gagamitin ang field hospital para sa mga mild at asymptomatic na OFW na pasyente.

Personal na ininspeksyon nina Health Secretary Francisco Duque III at National Task Force Against COVID-19 chief implementer Carlito Galvez Jr. at mga opisyal ng Bureau of Quarantine ang 344-bed capacity na field hospital.

Napabilib si Duque at sinabing pang-first class facility ang filed hospital na kumpleto sa mga kagamitan.

“The Manila government will shoulder the expenses until the ROFs complete their isolation here in the Manila Filed Hospital,” pahayag ni Moreno.

Matatandaang itinayo ang field hospital sa loob lamang ng 52 na araw.

Tiniyak din ni Moreno kay Duque na may sapat na suplay ng gamot kontra COVID-19 ang pamahalaang lungsod. Halimbawa na ang Remdesivir, Tocilizumab at Molnupiravir.

Aabot sa 40,000 na kapsula ng Molnupiravir ang binili ni Moreno.

“We should always be ahead of Covid infections. We were the first to purchase Remdesivir and Tocilizumab. And now this wonder drug Molnupiravir, tayo din ang naunang bumili. I will continue to listen to science,” pahayag ni Moreno.

“Iisang bangka tayo. Dito sa Maynila, welcome ang lahat. Sa abot ng aming makakaya, handa kaming tumulong sa ibang nangangailangan ng mga life-saving drugs gaya ng Remdisivir at Tocilizumab na maraming natulungan sa ibang lugar sa labas ng syudad,” dagdag ng alkalde.

 

 

TAGS: COVID-19, Manila COVID-19 Field Hospital, Manila Mayor Isko Moreno, COVID-19, Manila COVID-19 Field Hospital, Manila Mayor Isko Moreno

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.